Autor según el artículo: Sanchez-Lopez, Elena; Ettcheto, Miren; Antonia Egea, Maria; Espina, Marta; Cristina Calpena, Ana; Folch, Jaume; Camins, Antoni; Luisa Garcia, Maria
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Folch Lopez, Jaume
Palabras clave: Polyglactin 910 Polyethylene glycols Poly(lactic-glycolic acid)-poly(ethyleneglycol) copolymer Plga-peg Ocular delivery Nanospheres Nanoparticles Mouse model Mice, inbred c57bl Mice Memory Male Lipid nanoparticles In-vitro Ibuprofen Flurbiprofen Ex-vivo Drug-release Drug carriers Dried plga nanoparticles Disease models, animal Dexibuprofen Design Coculture techniques Cell line Brain Blood–brain barrier Blood-brain-barrier Blood-brain barrier Anti-inflammatory agents, non-steroidal Animals Alzheimer's disease Alzheimer disease nanospheres nanoparticles dexibuprofen blood–brain barrier alzheimer's disease
Resumen: Dexibuprofen loaded pegylated poly(lactic-co-glycolic) nanospheres prepared by solvent diffusion method were designed to increase Dexibuprofen brain delivery reducing systemic side effects. Nanospheres exhibited a mean particle size around 200 nm (195.4 nm), monomodal population and negative surface charge. Drug loaded nanospheres showed a sustained release profile, allowing to modify the posology in vivo. Nanospheres were non-toxic neither in brain endothelial cells nor astrocytes and do not cause blood¿brain barrier disruption. Nanospheres were able to partially cross the cells barrier and release the drug after co-culture in vitro experiments, increasing Dexibuprofen permeation coefficient. Behavioral tests performed in APPswe/PS1dE9 mice (mice model of familial Alzheimer's disease) showed that nanospheres reduce memory impairment more efficiently than the free drug. Developed nanospheres decrease brain inflammation leading to ¿-amyloid plaques reduction. According to these results, chronical oral Dexibuprofen pegylated poly(lactic-co-glycolic) nanosystems could constitute a suitable strategy for the prevention of neurodegeneration.
Áreas temáticas: Química Psicología Pharmaceutical science Odontología Nanoscience and nanotechnology Nanoscience & nanotechnology Molecular medicine Medicine, research & experimental Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materials science (miscellaneous) Materials science (all) Materiais Interdisciplinar General medicine General materials science Farmacia Engenharias iv Engenharias iii Engenharias ii Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências agrárias i Biotecnología Biomedical engineering Bioengineering Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 15499634
Direcció de correo del autor: jaume.folch@urv.cat
Identificador del autor: 0000-0002-5051-8858
Fecha de alta del registro: 2024-10-19
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://www.sciencedirect.com/science/article/abs/pii/S1549963416302209?via%3Dihub
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Nanomedicine-Nanotechnology Biology And Medicine. 13 (3): 1171-1182
Referencia de l'ítem segons les normes APA: Sanchez-Lopez, Elena; Ettcheto, Miren; Antonia Egea, Maria; Espina, Marta; Cristina Calpena, Ana; Folch, Jaume; Camins, Antoni; Luisa Garcia, Maria (2017). New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APPswe/PS1dE9. Nanomedicine-Nanotechnology Biology And Medicine, 13(3), 1171-1182. DOI: 10.1016/j.nano.2016.12.003
DOI del artículo: 10.1016/j.nano.2016.12.003
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2017
Tipo de publicación: Journal Publications
Repositori URV